Brief: Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
21/10/2025 13:09
Oct 21 (Reuters) - Citius Pharmaceuticals Inc CTXR.O: CITIUS PHARMACEUTICALS ANNOUNCES A REGISTERED DIRECT OFFERING OF $6.0 MILLION PRICED AT-THE-MARKET UNDER NASDAQ RULES Source text: ID:nPn1B0rLQa Further company coverage: CTXR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules